Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Roxifiban. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Roxifiban SCHEMBL24336949 | 0.98 | ITGB3 (1.00) | ITGB3ITGA2B | |
| Roxifiban SCHEMBL344302 | 0.98 | ITGB3 (1.00) | ITGB3ITGA2B | |
| SCHEMBL7213400 | 0.93 | ITGB3 (1.00) | ITGB3ITGA2B | |
| Roxifiban SCHEMBL50632 | 0.91 | ITGB3 (0.86) | ITGB3ITGA2B | |
| SCHEMBL7220986 | 0.89 | ITGB3 (0.83) | ITGB3ITGA2B | |
| SCHEMBL7413714 | 0.88 | ITGB3 (0.80) | ITGB3ITGA2B | |
| SCHEMBL7407564 | 0.88 | ITGB3 (0.80) | ITGB3ITGA2B | |
| SCHEMBL7229682 | 0.85 | ITGB3 (0.74) | ITGB3ITGA2B | |
| SCHEMBL7214664 | 0.84 | ITGB3 (0.76) | ITGB3ITGA2B | |
| SCHEMBL7217243 | 0.84 | ITGB3 (0.76) | ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 348 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1363668-B1 | COMBINATIONS OF BILE ACID SEQUESTRANT(S) AND STEROL ABSORPTION INHIBITOR(S) AND TREATMENTS FOR VASCULAR INDICATIONS | SCHERING CORP (US) | 2007-08-15 | — | — | EP | claimed |
| EP-1810693-A2 | Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions | Shering Corporation (US) | 2007-07-25 | — | — | EP | claimed |
| EP-1785144-A2 | Combinations of bile acids sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications | Shering Corporation (US) | 2007-05-16 | — | — | EP | claimed |
| CN-1658903-A | Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications | SCHERING CORP (US) | 2005-08-24 | — | — | CN | claimed |
| EP-1377309-A1 | COMBINATIONS OF HEPARIN COFACTOR II AGONIST AND PLATELET IIB/IIIA ANTAGONIST, AND USES THEREOF | IntimaX Corporation (US) | 2004-01-07 | — | — | EP | claimed |
| EP-1353694-A2 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH BLOOD MODIFIER(S) FOR TREATING VASCULAR CONDITIONS | Schering Corporation (US) | 2003-10-22 | — | — | EP | claimed |
| US-6624311-B2 | Forming roxifiban | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-09-23 | — | — | US | claimed |
| US-6518244-B2 | Combinations of heparin cofactor II agonist and platelet IIb/IIIa antagonist, and uses thereof | INTIMAX CORPORATION | 2003-02-11 | — | — | US | claimed |
| EP-0939900-A4 | DETECTION OF ANTAGONIST-DEPENDENT GPIIb/IIIa RECEPTOR ANTIBODIES | MERCK & CO INC (US) | 2003-01-08 | — | — | EP | claimed |
| US-20020160465-A1 | Enantioselective enzymatic aminolysis of a racemic 2-isoxazolylacetate alkyl ester | BRITOL-MYERS SQUIBB COMPANY (FORMERLY D/B/A DUPONT PHARMACEUTICALS COMPANY) | 2002-10-31 | — | — | US | claimed |
| US-6210904-B1 | DIAGNOSING FOR RISK OF THROMOCYTOPENIA BY DETECTING ABSENCE OF ASSOCIATION OF MONOCLONAL ANTIBODY WITH GLYCOPROTEIN IIB/IIA RECEPTOR:GLYCOPROTEIN IIB/IIA RECEPTOR ANTAGONIST COMPLEX | MERCK & CO., INC. | 2001-04-03 | — | — | US | claimed |
| US-6136804-A | ANTIISCHEMIC AGENTS, ANTITHROMBOTIC AGENTS, THROMBOTIC OCCLUSION AND ANTIPLATELET AGENT | MERCK & CO., INC. (US) | 2000-10-24 | — | — | US | claimed |
| EP-1034256-A1 | ANTICOAGULANT TEST | Merck & Co., Inc. (US) | 2000-09-13 | — | — | EP | claimed |
| US-6063584-A | Anticoagulant test | MERCK & CO., INC. (US) | 2000-05-16 | — | — | US | claimed |
| US-5978698-A | Angioplasty procedure using nonionic contrast media | MERCK & CO., INC. (US) | 1999-11-02 | — | — | US | claimed |
| EP-0939900-A1 | DETECTION OF ANTAGONIST-DEPENDENT GPIIb/IIIa RECEPTOR ANTIBODIES | Merck & Co., Inc. (US) | 1999-09-08 | — | — | EP | claimed |
| EP-0914099-A1 | ORAL COATED ACTIVE DRUGS | Merck & Co., Inc. (US) | 1999-05-12 | — | — | EP | claimed |
| WO-1999019463-A1 | ANTICOAGULANT TEST | MERCK & CO., INC. (US) | 1999-04-22 | — | — | WO | claimed |
| WO-1998022821-A1 | DETECTION OF ANTAGONIST-DEPENDENT GPIIb/IIIa RECEPTOR ANTIBODIES | MERCK & CO., INC. (US) | 1998-05-28 | — | — | WO | claimed |
| WO-1997037641-A1 | ORAL COATED ACTIVE DRUGS | MERCK & CO., INC. (US) | 1997-10-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020160465-A1 | Enantioselective enzymatic aminolysis of a racemic 2-isoxazolylacetate alkyl ester | ANPEP, DAO, DNPEP | ITGB3 128/4885ITGA2B 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.